Introduction
============

Gastrointestinal cancer, mainly including gastric cancer (GC) and colorectal cancer (CRC), is a major health problem that accounts for a large proportion of all human malignancies;[@b1-ott-8-1503] worldwide, approximately 3.25 million people are diagnosed with the disease each year.[@b2-ott-8-1503] Despite recent advances in the diagnosis and therapy of this disease, most GC and CRC patients present with advanced disease, accompanied by a poor prognosis and a low survival rate. With the development and advancement of comprehensive cancer treatment modalities, the prognosis of patients with GC and CRC has improved. However, long-term survival of these patients remains unsatisfactory. Invasion and metastasis are the most important biological characteristics of malignant tumors and the main cause of death.[@b3-ott-8-1503] The molecular mechanisms involved in invasion and metastasis of gastrointestinal cancer remain unclear. Thus, identifying the biological indicators of invasion and metastasis, especially with regard to the prognosis of GC and CRC, is particularly important.

Urokinase plasminogen activator (uPA) is a serine protease that is first secreted as a proenzyme, and then activated by proteolytic cleavage after binding to its specific cell-surface receptor, urokinase plasminogen activator receptor (uPAR).[@b4-ott-8-1503] In many human cancers, uPAR is overexpressed in the tumor-stromal invasive microenvironment.[@b5-ott-8-1503] By regulating and targeting proteolysis at the invading edge of a tumor, uPAR plays a critical role in cancer progression through its interaction with integrins and vitronectin and as a regulator of angiogenesis.[@b6-ott-8-1503] Previous studies have shown that uPAR expression was associated with poor prognosis and survival of patients with malignancies.[@b7-ott-8-1503]--[@b9-ott-8-1503] We reviewed studies in the literature on the relationship between uPAR and gastrointestinal cancer and found inconsistent conclusions. Therefore, we conducted a meta-analysis of all available studies to evaluate the association between uPAR expression and clinical outcome of patients with GC and CRC.

Materials and methods
=====================

Publication search
------------------

The PubMed database was searched for material published in English; the latest search was updated on November 20, 2014. The searching strategy consisted of combinations of medical subheadings and keywords, such as "gastric cancer" or "colorectal cancer", and "urokinase plasminogen activator receptor" or "uPAR" or "urokinase plasminogen activator system". All references cited in the original studies or review articles concerning the relevant topic were retrieved to broaden the search for relevant publications. Literature screening was independently performed by two reviewers (Hong Guo and Chun Ling).

Inclusion and exclusion criteria
--------------------------------

For this meta-analysis, publications of studies that met the following criteria were included: 1) inclusion of patients with GC or CRC; 2) investigation of the relationship between uPAR expression and the clinical outcome of patients; 3) primary outcomes of interest with clinicopathological features and prognosis; and 4) detection of uPAR in tissues with GC or CRC. The following exclusion criteria were used: 1) uPAR detection in patient's blood circulation, effusion, or cerebrospinal fluid; 2) uPAR expression in other gastrointestinal cancers, such as hepatocellular cancer and biliary/cholangio cancer; 3) abstracts and reviews; 4) studies without available or exactable data; 5) articles published in a language other than English; 6) repeated or overlapping publications; and 7) animal experiments or literature reviews.

Data extraction
---------------

Two authors (Yun-yun Ma and Lan-xia Zhou) independently extracted the following from the included studies: name of the first author, publication year of the article, country or area, tumor type (GC or CRC), number of patients, clinicopathological parameters, and outcomes. In addition, the response to chemotherapy according to genotype and the hazard ratios (HRs) for overall survival (OS) and their 95% confidence intervals (CIs) were collected for statistical analyses. Any discrepancies were resolved through discussion or consultation with a third person (Li Zhao).

Statistical analysis
--------------------

A chi-square-based *Q*-test was used to test the assumption of heterogeneity. *P*\>0.1 for the *Q*-test suggested a lack of heterogeneity among studies and required the use of the fixed effects model (the Mantel--Haenszel method) to estimate the pooled odds ratio (OR) of each study. Otherwise, the random effects model was used. OS was evaluated by using pooled Cox proportional HRs and 95% CIs. Statistical analyses were performed using Comprehensive Meta-Analysis software (Version 2.0). *P*\<0.05 was considered statistically significant, and all *P*-values were two sided.

Results
=======

Characteristics of studies used in meta-analysis
------------------------------------------------

This meta-analysis adheres to the relevant criteria of the Preferred Reporting Items for Systemic Reviews and Meta-Analyses (PRISMA) statement.[@b10-ott-8-1503] According to the search strategy, we initially retrieved 173 articles. Sixty-five of these were excluded by professional software as duplicate publications. We then carefully read and analyzed the titles and abstracts of the remaining 108 articles, omitting 90 that met our exclusion criteria. After reading the full text of the remaining 18 articles, an additional eight were excluded. Finally, ten studies,[@b11-ott-8-1503]--[@b20-ott-8-1503] encompassing 2,082 patients, were included in our meta-analysis. The results of the search strategy for study selection are summarized in [Figure 1](#f1-ott-8-1503){ref-type="fig"}. Six of the studies involved GC patients; four involved patients with CRC. The studies mainly used three methods to evaluate uPAR expression in gastrointestinal cancer specimens: immunohistochemistry, tissue micro-arrays, and reverse transcriptase-polymerase chain reaction. The primary patient outcomes were OS and survival rates. Characteristics of the eligible studies are summarized in [Table 1](#t1-ott-8-1503){ref-type="table"}.

Correlation of uPAR expression with clinicopathological parameters
------------------------------------------------------------------

This meta-analysis did not detect heterogeneity among the published reports (*P*\>0.05). The fixed effects model was used to analyze the relationship between uPAR expression and the clinical characteristics of GC and CRC. Five reports comparing uPAR expression in GC and CRC with that in normal lung tissues showed that the uPAR expression rate in the cancer tissues was higher than that in normal tissues (OR =3.385; 95% CI =2.605--4.400; *P*=0.000) ([Figure 2](#f2-ott-8-1503){ref-type="fig"}). This meta-analysis also revealed a significant association between uPAR expression and lymph node metastasis (OR =1.366; 95% CI =1.086--1.718; *P*=0.008) ([Figure 3](#f3-ott-8-1503){ref-type="fig"}). Comparing the uPAR expression in stage I--II and III--IV patients suggested a significant association between positive uPAR expression and tumor stage (OR =3.076; 95% CI =2.330--4.061; *P*=0.000) ([Figure 4](#f4-ott-8-1503){ref-type="fig"}). Specifically, higher uPAR expression indicates local and distant metastasis of tumor cells. In contrast, uPAR expression did not significantly correlate with tumor size, depth of invasion, tumor differentiation, or serosal invasion.

Effect of uPAR expression on OS of gastrointestinal cancer
----------------------------------------------------------

Of the ten studies included in our meta-analysis, six discussed the relationship between uPAR expression and OS of patients with GC and CRC. High uPAR expression correlated with poor OS (OR =1.937; 95% CI =1.570--2.930; *P*=0.000) ([Figure 5](#f5-ott-8-1503){ref-type="fig"}), indicating that uPAR is an independent prognostic factor in GC and CRC. No significant publication bias of OS was detected by the Funnel plot ([Figure 6](#f6-ott-8-1503){ref-type="fig"}).

Discussion
==========

To our knowledge, this is the first English meta-analysis to systematically determine the association between uPAR expression and survival of patients with GC and CRC. The clinicopathologic features and prognostic significance of uPAR expression in GC and CRC are controversial. Although the majority of studies suggest that uPAR expression in GC and CRC is significantly associated with lymph node and distant metastasis, and poor prognosis, the conclusions of Kaneko et al[@b14-ott-8-1503] and Minoo et al[@b17-ott-8-1503] are not consistent. Therefore, to obtain a more precise assessment of the role of uPAR in GC and CRC, we conducted a meta-analysis of ten eligible studies that included a total of 2,082 cases.

The expression and activation of uPA play an important role in tumorigenicity, and high endogenous levels of uPAR are associated with advanced cancers.[@b21-ott-8-1503] The uPAR is a 55--60 kDa glycoprotein that belongs to the Ly-6 family.[@b22-ott-8-1503] The gene encoding this receptor is located on chromosome 19q13.2, and is formed from seven exons separated by six introns.[@b23-ott-8-1503] To date, uPARs have been identified on the surface of monocytes, granulocytes, fibroblasts, keratinocytes, vascular endothelial cells, and cancer cells.[@b24-ott-8-1503] The binding of uPA to uPAR orchestrates different signaling molecules that mediate various biological responses, including proliferation, migration, invasion, angiogenesis, and metastasis.[@b25-ott-8-1503] Several technical approaches affecting tumor growth and metastasis, such as antisense oligodeoxynucleotides, adenoviral vectors, monoclonal antibodies, toxins, natural and synthetic inhibitors, and linear and cyclic uPA-derived peptides targeting the uPA--uPAR system in cancer patients at gene and protein levels, have been explored.[@b26-ott-8-1503]--[@b28-ott-8-1503] Tumor cell invasion is due to degradation of the extracellular matrix by proteases, and activation of the uPA--uPAR system initiates the destruction of various extracellular matrix proteins. Lymph node and distant metastases are the major prognostic factors in GC and CRC. In the meta-analysis presented here, we found that uPAR expression in GC and CRC tissues was markedly higher than in normal tissue. We also found that although uPAR expression was related to the status of lymph nodes and tumor node metastasis staging in an expanded sample, it was not significantly correlated with tumor size, depth of invasion, tumor differentiation, or serosal invasion. More importantly, higher expression of uPAR significantly correlated with poorer OS in GC and CRC, suggesting that uPAR may show promise as a prognostic indicator.

Some limitations need to be acknowledged in this meta-analysis. First, with 2,082 cases, the number of studies included was relatively small. Second, patient survival analyses were performed using only six studies, with detailed survival data reported in only a portion of these. We estimated survival information from HR and its 95% CI, which resulted in a certain degree of measurement bias. Third, it is clear that the two types of gastrointestinal cancer (GC and CRC) likely have different biological behaviors. Fourth, we were unable to assess the potential confounding variables in the individual studies, such as the method used for evaluation of uPAR expression and the choice of cutoff scores for positive staining. Fifth, some studies could not be included in our meta-analysis owing to the lack of detailed data or uPAR detected in blood samples. Sixth, we did not include other gastrointestinal adenocarcinomas in this study, for example, biliary/cholangio, esophageal, and pancreatic cancers. Hence, whether there is also abnormal expression of uPAR in these gastrointestinal adenocarcinomas is not clear, and this requires further study. In addition, most of the included studies were carried out in East Asia or Western countries, and the results may be different in other regions.

In conclusion, results of our meta-analysis indicate that uPAR expression is associated with the common clinicopathological parameters and outcomes of GC and CRC. Therefore, uPAR expression may serve as a novel disease marker in GC and CRC, as well as a therapeutic target.
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###### 

Characteristics of the eligible studies

  Authors                                  Country                      Year   N     Tumor stage   Tumor types   Measurement method   Cut off[a](#tfn1-ott-8-1503){ref-type="table-fn"}   Survival analysis
  ---------------------------------------- ---------------------------- ------ ----- ------------- ------------- -------------------- --------------------------------------------------- -------------------
  Alpízar-Alpízar et al[@b11-ott-8-1503]   Norway                       2012   95    I--IV         GC            ICH                  Score ≥1                                            OS
  Beyer et al[@b12-ott-8-1503]             Germany                      2006   104   I--IV         GC            ICH                  Score ≥1                                            OS
  Boonstra et al[@b13-ott-8-1503]          the Netherlands              2014   262   I--IV         CRC           TMA                  Score ≥50%                                          DFS, OS
  Kaneko et al[@b14-ott-8-1503]            Japan                        2003   101   --            GC            ICH                  Score ≥50%                                          OS
  Lee et al[@b15-ott-8-1503]               Korea                        2004   35    I--IV         GC            RT-PCR               --                                                  Survival rates
  Illemann et al[@b16-ott-8-1503]          Denmark                      2014   244   I--IV         CRC           ICH                  Score ≥0                                            OS
  Minoo et al[@b17-ott-8-1503]             USA                          2010   975   --            CRC           ICH                  Score ≥0                                            Survival rates
  Taniguchi et al[@b18-ott-8-1503]         Japan                        1998   102   --            GC            ICH                  Score ≥30%                                          OS
  Yang et al[@b19-ott-8-1503]              Australia                    2000   59    --            CRC           ICH                  Score ≥0                                            OS
  Zhang et al[@b20-ott-8-1503]             People's Republic of China   2006   105   --            GC            ICH                  Score ≥50%                                          Survival rates

**Note:**

Cut off of uPAR high expression.

**Abbreviations:** N, number of patients; GC, gastric cancer; ICH, immunohistochemistry; OS, overall survival; CRC, colorectal cancer; TMA, tissue micro-arrays; DFS, disease-free survival; RT-PCR, reverse transcriptase-polymerase chain reaction; uPAR, urokinase plasminogen activator receptor.
